This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mukherjee, P. K. Articles by Ghannoum, M. A. Search for Related Content PubMed PubMed Citation Articles by Mukherjee, P. K. Articles by Ghannoum, M. A.

Combination Treatment of Invasive Fungal Infections

Center for Medical Mycology, Case Western Reserve University and University Hospitals of Cleveland, Cleveland, Ohio,¹ Pfizer Global Pharmaceuticals, Pfizer Inc., New York, New York,² Exploratory Development, Pfizer Global Research & Development, Sandwich Laboratories, Sandwich, United Kingdom³

The persistence of high morbidity and mortality from systemic fungal infections despite the availability of novel antifungals points to the need for effective treatment strategies. Treatment of invasive fungal infections is often hampered by drug toxicity, tolerability, and specificity issues, and added complications often arise due to the lack of diagnostic tests and to treatment complexities. Combination therapy has been suggested as a possible approach to improve treatment outcome. In this article, we undertake a historical review of studies of combination therapy and also focus on recent studies involving newly approved antifungal agents. The limitations surrounding antifungal combinations include nonuniform interpretation criteria, inability to predict the likelihood of clinical success, strain variability, and variations in pharmacodynamic/pharmacokinetic properties of antifungals used in combination. The issue of antagonism between polyenes and azoles is beginning to be addressed, but data regarding other drug combinations are not adequate for us to draw definite conclusions. However, recent data have identified potentially useful combinations. Standardization of assay methods and adoption of common interpretive criteria are essential to avoid discrepancies between different in vitro studies. Larger clinical trials are needed to assess whether combination therapy improves survival and treatment outcome in the most seriously debilitated patients afflicted with life-threatening fungal infections.

This article has been cited by other articles:

• Sandovsky-Losica, H., Shwartzman, R., Lahat, Y., Segal, E. (2008). Antifungal activity against Candida albicans of nikkomycin Z in combination with caspofungin, voriconazole or amphotericin B. J Antimicrob Chemother 0: dkn216v1-2 [Full Text]  
• Serena, C., Marine, M., Quindos, G., Carrillo, A. J., Cano, J. F., Pastor, F. J., Guarro, J. (2008). In Vitro Interactions of Micafungin with Amphotericin B against Clinical Isolates of Candida spp.. Antimicrob. Agents Chemother. 52: 1529-1532 [Abstract] [Full Text]  
• Guo, Q., Sun, S., Yu, J., Li, Y., Cao, L. (2008). Synergistic activity of azoles with amiodarone against clinically resistant Candida albicans tested by chequerboard and time-kill methods. J Med Microbiol 57: 457-462 [Abstract] [Full Text]  
• Spreghini, E., Maida, C. M., Milici, M. E., Scalise, G., Barchiesi, F. (2008). Posaconazole Activity against Candida glabrata after Exposure to Caspofungin or Amphotericin B. Antimicrob. Agents Chemother. 52: 513-517 [Abstract] [Full Text]  
• Sun, S., Li, Y., Guo, Q., Shi, C., Yu, J., Ma, L. (2008). In Vitro Interactions between Tacrolimus and Azoles against Candida albicans Determined by Different Methods. Antimicrob. Agents Chemother. 52: 409-417 [Abstract] [Full Text]  
• Singh, K., Boileau, M. J., Streeter, R. N., Welsh, R. D., Meier, W. A., Ritchey, J. W. (2007). Granulomatous and Eosinophilic Rhinitis in a Cow Caused by Pseudallescheria boydii Species Complex (Anamorph Scedosporium apiospermum). Vet Pathol 44: 917-920 [Abstract] [Full Text]  
• Guembe, M., Guinea, J., Pelaez, T., Torres-Narbona, M., Bouza, E. (2007). Synergistic Effect of Posaconazole and Caspofungin against Clinical Zygomycetes. Antimicrob. Agents Chemother. 51: 3457-3458 [Full Text]  
• Pedreno, Y., Gonzalez-Parraga, P., Martinez-Esparza, M., Sentandreu, R., Valentin, E., Arguelles, J.-C. (2007). Disruption of the Candida albicans ATC1 gene encoding a cell-linked acid trehalase decreases hypha formation and infectivity without affecting resistance to oxidative stress. Microbiology 153: 1372-1381 [Abstract] [Full Text]  
• Morris, M. I., Villmann, M. (2006). Echinocandins in the management of invasive fungal infections, part 2.. Am J Health Syst Pharm 63: 1813-1820 [Abstract] [Full Text]  
• Ellis, M., Frampton, C., Joseph, J., Alizadeh, H., Kristensen, J., Hauggaard, A., Shammas, F. (2006). An open study of the comparative efficacy and safety of caspofungin and liposomal amphotericin B in treating invasive fungal infections or febrile neutropenia in patients with haematological malignancy.. J Med Microbiol 55: 1357-1365 [Abstract] [Full Text]  
• Bopp, L. H., Baltch, A. L., Ritz, W. J., Michelsen, P. B., Smith, R. P. (2006). Antifungal effect of voriconazole on intracellular Candida glabrata, Candida krusei and Candida parapsilosis in human monocyte-derived macrophages.. J Med Microbiol 55: 865-870 [Abstract] [Full Text]  
• Bow, E. J. (2006). Of Yeasts and Hyphae: A Hematologist's Approach to Antifungal Therapy. ASH Education Book 2006: 361-367 [Abstract] [Full Text]  
• Serena, C., Marine, M., Pastor, F. J., Nolard, N., Guarro, J. (2005). In vitro interaction of micafungin with conventional and new antifungals against clinical isolates of Trichosporon, Sporobolomyces and Rhodotorula. J Antimicrob Chemother 55: 1020-1023 [Abstract] [Full Text]  
• Avis, I., Martinez, A., Tauler, J., Zudaire, E., Mayburd, A., Abu-Ghazaleh, R., Ondrey, F., Mulshine, J. L. (2005). Inhibitors of the Arachidonic Acid Pathway and Peroxisome Proliferator-Activated Receptor Ligands Have Superadditive Effects on Lung Cancer Growth Inhibition. Cancer Res. 65: 4181-4190 [Abstract] [Full Text]